Bone Sialoprotein (BSP) is a Crucial Factor for the Expression of Osteoblastic Phenotypes of Bone Marrow Cells Cultured on Type I Collagen Matrix

2000 ◽  
Vol 66 (5) ◽  
pp. 388-396 ◽  
Author(s):  
M. Mizuno ◽  
T. Imai ◽  
R. Fujisawa ◽  
H. Tani ◽  
Y. Kuboki
Keyword(s):  
Bone Marrow ◽  
Type I Collagen ◽  
Bone Marrow Cells ◽  
Collagen Matrix ◽  
Bone Sialoprotein ◽  
Type I ◽  
Cells Cultured ◽  
Marrow Cells

Abstract 1861: Myocardial Assistance by Grafting a New Bioartificial Upgraded Myocardium (MAGNUM Clinical Trial): One Year Outcome

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Juan Chachques ◽  
Jorge Trainini ◽  
Miguel Cortes-Morichetti ◽  
Olivier Schussler ◽  
Alain Carpentier
Keyword(s):  
Bone Marrow ◽  
Extracellular Matrix ◽  
Type I Collagen ◽  
Bone Marrow Cells ◽  
Collagen Matrix ◽  
Type I ◽  
Intramyocardial Injection ◽  
Cardiac Wall ◽  
A Cell

Objectives Cell transplantation for myocardial regeneration is limited by poor graft viability and low cell retention. In addition, in ischemic cardiomyopathy the extracellular matrix is deeply altered. Therefore it could be important to associate a procedure aiming at regenerating myocardial cells and restoring the extracellular matrix function. We evaluated intrainfarct stem cell therapy associated with a cell-seeded collagen scaffold grafted onto infarcted ventricles. Methods In 15 patients (aged 54.2±3.8 years) presenting LV postischemic myocardial scars (age of the infarcts 8.2±3.5 months) and with indication for a single OP-CABG, bone marrow was collected by aspiration from the iliac crest. The cell suspension was loaded on Ficoll-Paque density gradient and 300 ± 28 million mononuclear bone marrow cells (BMC) were implanted during surgery in the scar. A type I collagen matrix seeded with the same number of BMC (300 ± 28 million cells) was added on top of the scarred area and fixed onto the epicardium by 6 single PDS sutures and covered by a second non-cellularized matrix. Results There was no mortality and any related adverse events (follow-up 15±4.2 months), no malignant cardiac arrhythmias were reported, no patient was lost to follow-up. NYHA FC improved from 2.3±0.5 to 1.4±0.3 (p=0.005). LV end-diastolic volume evolved from 142±24 to 117±21mL (p=0.03), LV filling deceleration time improved from 162±7ms to 196±8ms (p=0.01). Scar area thickness progress from 6±1.4 to 9±1.5mm (p=0.005). EF improved from 25±7 to 33±5% (p=0.04). Conclusions Simultaneous intramyocardial injection of BMC and fixation of a cell seeded matrix onto the epicardium is feasible and safe. The cell seeded collagen matrix seems to increase the thickness of the infarct scar with viable tissues and help to normalize cardiac wall stress in injured regions, thus limiting ventricular remodelling and improving diastolic function. Functional improvements can not be conclusively related to the cells and matrix due to the association of CABG. Cardiac tissue engineering seems to be a promising way for the creation of “bioartificial myocardium”. Efficacy and safety of this approach should be evaluated in a large randomized controlled trial.

Myocardial Assistance by Grafting a New Bioartificial Upgraded Myocardium (MAGNUM Clinical Trial): One Year Follow-Up

2007 ◽  
Vol 16 (9) ◽  
pp. 927-934 ◽  
Author(s):  
Juan C. Chachques ◽  
Jorge C. Trainini ◽  
Noemi Lago ◽  
Osvaldo H. Masoli ◽  
Jose L. Barisani ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Extracellular Matrix ◽  
Cell Therapy ◽  
Bone Marrow Cells ◽  
Type I ◽  
Intramyocardial Injection ◽  
Cardiac Wall ◽  
Mononuclear Bone Marrow Cells ◽  
Marrow Cells

Cell transplantation for the regeneration of ischemic myocardium is limited by poor graft viability and low cell retention. In ischemic cardiomyopathy the extracellular matrix is deeply altered; therefore, it could be important to associate a procedure aiming at regenerating myocardial cells and restoring the extracellular matrix function. We evaluated intrainfarct cell therapy associated with a cell-seeded collagen scaffold grafted onto infarcted ventricles. In 15 patients (aged 54.2 ± 3.8 years) presenting LV postischemic myocardial scars and with indication for a single OP-CABG, autologous mononuclear bone marrow cells (BMC) were implanted during surgery in the scar. A 3D collagen type I matrix seeded with the same number of BMC was added on top of the scarred area. There was no mortality and no related adverse events (follow-up 15 ± 4.2 months). NYHA FC improved from 2.3 ± 0.5 to 1.4 ± 0.3 (p = 0.005). LV end-diastolic volume evolved from 142 ± 24 to 117 ± 21 ml (p = 0.03), and LV filling deceleration time improved from 162 ± 7 to 196 ± 8 ms (p = 0.01). Scar area thickness progressed from 6 ± 1.4 to 9 ± 1.5 mm (p = 0.005). EF improved from 25 ± 7% to 33 ± 5% (p = 0.04). Simultaneous intramyocardial injection of mononuclear bone marrow cells and fixation of a BMC-seeded matrix onto the epicardium is feasible and safe. The cell-seeded collagen matrix seems to increase the thickness of the infarct scar with viable tissues and helps to normalize cardiac wall stress in injured regions, thus limiting ventricular remodeling and improving diastolic function. Patients' improvements cannot be conclusively related to the cells and matrix due to the association of CABG. Cardiac tissue engineering seems to extend the indications and benefits of stem cell therapy in cardiology, becoming a promising way for the creation of a “bioartificial myocardium.” Efficacy and safety of this approach should be evaluated in a large randomized controlled trial.

Treatment of non-healing wounds with autologous bone marrow cells, platelets, fibrin glue and collagen matrix

Cytotherapy ◽  
2011 ◽  
Vol 13 (6) ◽  
pp. 705-711 ◽  
Author(s):  
Hassan Ravari ◽  
Daryoush Hamidi-Almadari ◽  
Mohsen Salimifar ◽  
Shokofeh Bonakdaran ◽  
Mohammad Reza Parizadeh ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Fibrin Glue ◽  
Bone Marrow Cells ◽  
Autologous Bone Marrow ◽  
Collagen Matrix ◽  
Healing Wounds ◽  
Autologous Bone ◽  
Marrow Cells
Sign in / Sign up

Export Citation Format

Share Document